These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
89 related articles for article (PubMed ID: 6465106)
41. Post-marketing drug surveillance--concepts, insights and applications. Fassihi AR; Robertson SS S Afr Med J; 1990 Jun; 77(11):577-80. PubMed ID: 2189230 [TBL] [Abstract][Full Text] [Related]
42. Cimetidine and gastric cancer: preliminary report from post-marketing surveillance study. Colin-Jones DG; Langman MJ; Lawson DH; Vessey MP Br Med J (Clin Res Ed); 1982 Nov; 285(6351):1311-3. PubMed ID: 6812688 [TBL] [Abstract][Full Text] [Related]
43. Appropriateness of long-term cimetidine prescribing. Ulaszek KM; Seabloom KD; Sampliner RD; Jones WN Drug Intell Clin Pharm; 1984; 18(7-8):623-5. PubMed ID: 6430660 [TBL] [Abstract][Full Text] [Related]
44. Report on other drug use among persons previously reported to have received intravenous cimetidine. Jick H Arch Intern Med; 1992 Oct; 152(10):2145. PubMed ID: 1417393 [No Abstract] [Full Text] [Related]
47. Cimetidine-associated depression and loss of libido in a woman. Pierce JR Am J Med Sci; 1983; 286(3):31-4. PubMed ID: 6356917 [TBL] [Abstract][Full Text] [Related]
48. The side effects of cimetidine. Report of a case. Kiire CF Cent Afr J Med; 1985 Dec; 31(12):247-8. PubMed ID: 2939960 [No Abstract] [Full Text] [Related]
49. [Causes of death in patients treated with cimetidine--a phase 4 study]. Schmidt K; Mosbech J; Worsøe E Ugeskr Laeger; 1987 Aug; 149(34):2252-5. PubMed ID: 3330323 [No Abstract] [Full Text] [Related]
50. Innovation for Safe and Effective Medical Devices: Contributions From Postmarket Surveillance. Zippel C; Bohnet-Joschko S Ther Innov Regul Sci; 2017 Mar; 51(2):237-245. PubMed ID: 30231719 [TBL] [Abstract][Full Text] [Related]
51. Ten-Year Global Postmarket Safety Surveillance of Delayed Complications With a Flexible Cheek Filler. Cohen JL; Patel M; Hicks J Dermatol Surg; 2022 Oct; 48(10):1126-1127. PubMed ID: 36129206 [No Abstract] [Full Text] [Related]
52. The Value of A Postmarket Knowledge Exchange. Maeder T Biomed Instrum Technol; 2015; 49(6):452. PubMed ID: 26618843 [No Abstract] [Full Text] [Related]
53. Current development in medical devices postmarket surveillance in Taiwan. Lan CW; Yeh MK; Wu SI; Tu PW J Food Drug Anal; 2015 Mar; 23(1):164-165. PubMed ID: 28911441 [No Abstract] [Full Text] [Related]
54. Improving FDA postmarket adverse event reporting for medical devices. Wunnava S; Miller TA; Bourgeois FT BMJ Evid Based Med; 2023 Apr; 28(2):83-84. PubMed ID: 35177481 [No Abstract] [Full Text] [Related]
55. Pharmacovigilance and expedited drug approvals. Linger M; Martin J Aust Prescr; 2018 Apr; 41(2):50-53. PubMed ID: 29670312 [No Abstract] [Full Text] [Related]
56. Postmarket surveillance of high-risk medical devices needs transparent, comprehensive and independent registries. Fraser AG BMJ Surg Interv Health Technol; 2020; 2(1):e000065. PubMed ID: 35051246 [No Abstract] [Full Text] [Related]
57. Correction to "Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting". Clin Pharmacol Ther; 2023 Dec; 114(6):1387. PubMed ID: 37899631 [No Abstract] [Full Text] [Related]
59. Comparison of 200 mg cimetidine with multiple doses of antacid on extent and duration of rise in gastric pH in volunteers. Thomson AB; Kirdeikis P; Zuk L Dig Dis Sci; 1999 Oct; 44(10):2051-5. PubMed ID: 10548357 [TBL] [Abstract][Full Text] [Related]